StockData

Dianthus Therapeutics vs Vistagen Therapeutics

DNTH and VTGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DNTH and VTGN compare

Dianthus Therapeutics is the larger company, worth 599 times as much as Vistagen Therapeutics ($5.0B against $8.3M).

Vistagen Therapeutics scores higher on the StockData Score (9 against 7 for Dianthus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDNTHVTGN
Size and price
Market cap$5.0B$8.3M
Share price$89.30$0.188
Change, 1 year144%−95.3%
Change, 5 years−16.6%−99.7%
Beta (5Y)1.441.31
Employees9241
StockData Score
Total score79 (better)
Valuation score03 (better)
Growth score00
Performance score11
Health score6 (better)5
Dividend score00
Valuation
P/S–3.3×
P/B4.0×0.3× (better)
Fair value–$0.870
Margin of safety–78.4%
Growth
Revenue growth, 5Y average–3.1%
Profitability
Operating margin–−2784%
Net margin–−2703%
Return on equity−22.6% (better)−166%
Return on invested capital−22.2%–
Financial health
Debt / equity0.000.00
Current ratio30.02 (better)3.07
Altman Z-score85.71 (better)−24.35
Piotroski F-score22
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield−0.01%–
Shareholder yield−0.01%0.00% (better)
Ownership
Held by institutions118%26.5%
Held by insiders9.1%0.52%
Insider net buying, 12 months−$63.8M–
Short interest, % of float18.2%5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.